| dc.creator | Sandset E.C., Appleton J.P., Berge E., Christensen H., Gommans J., Krishnan K., Ntaios G., Phillips S., Pocock S., Sprigg N., Woodhouse L.J., Bath P.M. | en |
| dc.date.accessioned | 2023-01-31T09:53:51Z | |
| dc.date.available | 2023-01-31T09:53:51Z | |
| dc.date.issued | 2019 | |
| dc.identifier | 10.1097/HJH.0000000000002154 | |
| dc.identifier.issn | 02636352 | |
| dc.identifier.uri | http://hdl.handle.net/11615/78778 | |
| dc.description.abstract | Objectives:High blood pressure (BP) is associated with a poor outcome after acute stroke. Early reduction in BP may be associated with fewer early adverse events and deaths, and improved functional outcome.Methods:Analyses used data from the Efficacy of Nitric Oxide in Stroke trial, a multicentre randomized single-masked and outcome-masked trial of glyceryl trinitrate vs. no glyceryl trinitrate in 4011 patients recruited within 48h of an ischaemic or haemorrhagic stroke and with raised SBP (140-220mmHg). Change in SBP from baseline to day 1 was categorized as: more than 15% decrease, 15-5% decrease, 5% decrease to 5% increase (no change-reference) and more than 5% increase. The primary outcome was functional outcome (modified Rankin scale) score at 90 days.Results:Across all patients, both moderate (5-15%) and large (>15%) decreases in SBP were associated with beneficial shifts in the modified Rankin scale relative to patients with no change in BP: Adjusted common odds ratio (OR) 0.81 [95% confidence interval (CI) 0.70-0.90] and OR 0.84 (95% CI 0.71-1.00), respectively. A moderate decrease in SBP was also associated with a lower risk of early adverse events, adjusted OR 0.69 (95% CI 0.52-0.90).Conclusion:Modest decreases in SBP in acute stroke appear to be associated with fewer early events and better long-Term functional outcome. © 2019 Wolters Kluwer Health, Inc. All rights reserved. | en |
| dc.language.iso | en | en |
| dc.source | Journal of Hypertension | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071510641&doi=10.1097%2fHJH.0000000000002154&partnerID=40&md5=841d5010b92479219016d0f4c6f70138 | |
| dc.subject | glyceryl trinitrate | en |
| dc.subject | glyceryl trinitrate | en |
| dc.subject | vasodilator agent | en |
| dc.subject | adult | en |
| dc.subject | aged | en |
| dc.subject | Article | en |
| dc.subject | blood pressure | en |
| dc.subject | brain hemorrhage | en |
| dc.subject | brain ischemia | en |
| dc.subject | cardiac patient | en |
| dc.subject | cerebrovascular accident | en |
| dc.subject | controlled study | en |
| dc.subject | disease association | en |
| dc.subject | female | en |
| dc.subject | functional status | en |
| dc.subject | human | en |
| dc.subject | hypertension | en |
| dc.subject | major clinical study | en |
| dc.subject | male | en |
| dc.subject | multicenter study | en |
| dc.subject | outcome assessment | en |
| dc.subject | priority journal | en |
| dc.subject | randomized controlled trial | en |
| dc.subject | Rankin scale | en |
| dc.subject | single blind procedure | en |
| dc.subject | stroke patient | en |
| dc.subject | systolic blood pressure | en |
| dc.subject | blood pressure | en |
| dc.subject | cerebrovascular accident | en |
| dc.subject | clinical trial | en |
| dc.subject | drug effect | en |
| dc.subject | hypertension | en |
| dc.subject | middle aged | en |
| dc.subject | pathophysiology | en |
| dc.subject | physiology | en |
| dc.subject | treatment outcome | en |
| dc.subject | very elderly | en |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | Blood Pressure | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Hypertension | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Nitroglycerin | en |
| dc.subject | Single-Blind Method | en |
| dc.subject | Stroke | en |
| dc.subject | Treatment Outcome | en |
| dc.subject | Vasodilator Agents | en |
| dc.subject | Lippincott Williams and Wilkins | en |
| dc.title | Associations between change in blood pressure and functional outcome, early events and death: Results from the Efficacy of Nitric Oxide in Stroke trial | en |
| dc.type | journalArticle | en |